Page last updated: 2024-08-24

2-methoxyestradiol and Astrocytoma, Grade IV

2-methoxyestradiol has been researched along with Astrocytoma, Grade IV in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Durden, DL; Joshi, S; Kesari, S; Makale, MT; Muh, CR; Singh, AR1
Rivera-Delgado, E; von Recum, HA1
Barone, TA; Ciesielski, MJ; Fenstermaker, RA; Lis, A; Plunkett, RJ; Scott, BE1

Other Studies

3 other study(ies) available for 2-methoxyestradiol and Astrocytoma, Grade IV

ArticleYear
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
    Journal of neuro-oncology, 2014, Volume: 116, Issue:1

    Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Chromones; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Morpholines; PTEN Phosphohydrolase; Xenograft Model Antitumor Assays

2014
Using Affinity To Provide Long-Term Delivery of Antiangiogenic Drugs in Cancer Therapy.
    Molecular pharmaceutics, 2017, 03-06, Volume: 14, Issue:3

    Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cellulose; Cyclodextrins; Drug Delivery Systems; Estradiol; Female; Glioblastoma; Humans; Indoles; Mice; Mice, Nude; ortho-Aminobenzoates; Pyrroles; Silybin; Silymarin

2017
2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro.
    Cancer letters, 2004, Sep-15, Volume: 213, Issue:1

    Topics: 2-Methoxyestradiol; Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Estradiol; Female; Glioblastoma; Humans; Neoplasms, Experimental; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation

2004